COMPANY PROFILE

IpiNovyx Bio

Developing multiple series of highly selective, ultra potent small molecule therapeutics for the treatment of autoimmune and inflammatory disorders

Cincinnati, United StatesFounded 2021Biotech & Life Sciences

Valuation $50–100M Last recorded · 2021

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About IpiNovyx Bio

IpiNovyx Bio is a biopharmaceutical company that is developing a platform of immunoproteasome-modulating therapeutics to treat autoimmune and inflammatory diseases. The company's drug development candidates are based on its proprietary technology platform, which allows for the creation of highly-selective and potent small molecule therapeutics.

IpiNovyx Bio's lead compounds are highly selective for the immunoproteasome, which is a type of proteasome that is involved in the immune system. This selectivity allows the company's drugs to target the immune system without affecting other parts of the body. The company is developing its drugs for the treatment of a variety of autoimmune and inflammatory diseases, including lupus, rheumatoid arthritis, and multiple sclerosis.

The company has raised $10 million in seed financing from a syndicate of investors that includes Viva BioInnovator, Eli Lilly and Company, and HSS. The company is using this funding to advance its lead drug candidates toward first-in-human clinical studies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2021
Headquarters: Cincinnati, United States
Employees: 5
Open positions: None listed
Dealroom signal: 64.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEED✓Equity / VC	Oct 2021	$10M	$40M	Orange Grove Bio · Lilly Ventures · Alexandria Venture Investments · Opaleye Management	↗
SPINOUT✓Other financing	Jan 2021	—	—	Cornell Tech · Cornell University	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

IpiNovyx Bio website traffic

Latest recorded traffic for IpiNovyx Bio is 180 monthly website visits. IpiNovyx Bio's team grew 0% over the past year.

Latest monthly visits180 1-year team growth0%

Monthly website visitsMay 2023–Jun 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DTDraig TherapeuticsTargeted neuromodulators for major neuropsychiatric disorders treatment	Cardiff, United Kingdom	Operational	44	$217M	$700M
XBXanadu BioPioneering cystic fibrosis treatment through small molecules and gene editing	Lower Merion Township, United States	Operational
STSolve TherapeuticsTargeted cancer therapies enhancing safety and precision	San Diego, United States	Operational
3535PharmaAdvancing therapeutic biologics to treat cardiopulmonary and metabolic diseases	Montreal, Canada	Acquired
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
BIBioCaptivaNovel liquid biopsy device for cancer diagnostics	St Andrews, United Kingdom	Operational
MBMICA BiosystemsBiomagnetic technology for remote-controlled regenerative medicine applications	Solihull, United Kingdom	Operational